Wave Life Scienc Stock Price, News & Analysis

Wave Life Sciences announced the publication of preclinical data for WVE-004, targeting C9orf72-associated ALS and frontotemporal dementia. The study, published in Molecular Therapy Nucleic Acids, demonstrated significant reductions in pathogenic RNA transcripts and poly(GP) proteins over six months in mice, highlighting its potential efficacy. Initial clinical data from the ongoing FOCUS-C9 trial suggests that these preclinical results are translating into human applications, with effective target engagement and sustained reductions in poly(GP) levels.

Wave Life Sciences Ltd. (Nasdaq: WVE) will participate in Chardan’s 6th Annual Genetic Medicines & Cell Therapy Manufacturing Summit on April 26, 2022, at 2:30 p.m. ET. CEO Paul Bolno and SVP Sri Vaddeboina will join an analyst-led fireside chat, which will be streamed live on their Investor Relations page. Wave Life Sciences focuses on delivering innovative genetic medicines for devastating diseases using its PRISM platform for the precise design and production of stereopure oligonucleotides. A replay will be available shortly after the event on their website.

Wave Life Sciences (Nasdaq: WVE) announced positive updates from its Phase 1b/2a FOCUS-C9 trial for WVE-004, targeting C9orf72-associated ALS and frontotemporal dementia. Key findings include significant reductions in poly(GP) levels indicating target engagement, with a 34% decrease observed post a 30 mg single dose. The dosing observation period will now extend to six months to assess maximum poly(GP) reduction. Multidose cohorts at 10 mg are underway, with further data expected throughout 2022, reinforcing the trial’s adaptive design and the potential of its proprietary PN chemistry.

Wave Life Sciences Ltd. (Nasdaq: WVE) announced that CEO Paul Bolno will participate in a virtual fireside chat at the Stifel 2022 CNS Days event on March 28, 2022, at 9:15 a.m. EDT. This event highlights Wave's commitment to developing genetic medicines aimed at treating severe diseases. A live webcast of the presentation will be available on the Investor Relations page of Wave's website, with a replay available for a limited time after the event.

Wave Life Sciences Ltd. (Nasdaq: WVE) announced key presentations at the OPT Congress and RNA Editing Summit, showcasing advancements in their A-to-I(G) RNA base editing oligonucleotides (AIMers). Highlights include preclinical data on their AIMer program for Alpha-1 antitrypsin deficiency (AATD), demonstrating editing efficiency and protein restoration over 19 weeks. The AIMers leverage the body's natural ADAR enzymes for precise editing without permanent genomic changes. The company's IND-enabling studies are slated for Q3 2022, emphasizing Wave's commitment to innovative genetic therapies.

Wave Life Sciences (Nasdaq: WVE) announced preclinical proof-of-concept data demonstrating the efficacy of its AIMer technology for RNA base editing in non-human primates. Published in Nature Biotechnology, the study reported up to 50% editing of the ACTB transcript in the liver, with levels persisting at 40% for over a month. AIMers simplify delivery without the need for exogenous enzymes, potentially enhancing therapeutic applications, especially for genetic conditions like alpha-1 antitrypsin deficiency.

Wave Life Sciences (WVE) reported a net loss of $34.8 million for Q4 2021, compared to $28.8 million in Q4 2020. For the full year, the net loss was $122.2 million, down from $149.9 million in 2020. Revenue from the Takeda collaboration fell to $1.8 million in Q4 from $9.4 million in the previous year, while total revenue for 2021 reached $41.0 million, up from $20.1 million. Cash as of December 31, 2021, stood at $150.6 million, expected to fund operations into Q2 2023. Key developments include advancements in RNA therapies for ALS, DMD, and HD.

Wave Life Sciences (Nasdaq: WVE) will hold a live webcast and conference call on March 3, 2022, at 8:30 a.m. ET to discuss its Q4 and FY 2021 financial results and provide a business update. The webcast can be accessed via the Investor Relations section of the Wave Life Sciences website. The company's proprietary PRISM platform focuses on developing genetic medicines, targeting genetically defined diseases. Investors can dial in for the call using provided numbers and enter the conference ID: 7694386. An archived version will be available post-event.

Wave Life Sciences (Nasdaq: WVE) announced that CEO Paul Bolno will participate in an analyst-led fireside chat at the Virtual 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 10:40 a.m. ET. The event underscores Wave's commitment to advancing genetic medicines for severe diseases. A live webcast will be accessible on their Investor Relations page, and a replay will be available for a limited time after the event. Wave Life Sciences focuses on creating innovative treatments using their proprietary PRISM platform.